Rilotumumab is a human IgG2 monoclonal antibody that binds to HGF and inhibits c-Met-mediated signal transduction. Rilotumumab has been investigated as the treatment of solid tumors.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.